Long-Term Phase 3 Study of Cantharidin YCANTHVP-102TO-208 to Treat Common Warts with Follow-Up for Safety and Effectiveness

What this Trial Is About

Researchers are evaluating the long-term safety and effectiveness of a treatment called YCANTH also known as VP-102 or TO-208 for people with common warts who previously participated in related studies COVE-2 or COVE-3. This phase 3, open-label study aims to monitor side effects, including expected local skin reactions, and to assess how well repeated applications of YCANTH clear common warts over time. Participants with warts at the start of the study will receive YCANTH applied directly to each wart every 21 days, up to four additional treatments or until all warts clear. After clearance, participants will have observation visits every 42 days without treatment, but if new warts appear, treatment will resume. The study includes careful wart preparation, application of the drug with occlusive tape overnight, and monitoring of skin reactions. The entire study lasts approximately 294 days from parent study completion to the final visit on Day 378. Throughout the study, participants will attend treatment and observation visits where researchers will evaluate wart clearance, skin reactions, vital signs, and medication use. Detailed assessments include wart counts, photographic documentation for those who consent, and monitoring for adverse events. Participants must follow study instructions, including limiting certain water exposures after treatment, and will be observed until the study ends on Day 378.

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)